Advertisment Fosfocin
Indian Journal of Critical Care Medicine
An open access publication of ISCCM™ 
 
Users online: 417 
     Home | Login 
  About Current Issue Archive Search Instructions Online Submission Subscribe Etcetera Contact  
  NAVIGATE Here 
  Search
 
  
 RESOURCE Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (850 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free) 

  IN THIS Article
  Acknowledgment
   References
   Article Figures

 Article Access Statistics
    Viewed1178    
    Printed20    
    Emailed0    
    PDF Downloaded292    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2013  |  Volume : 17  |  Issue : 5  |  Page : 325-326

Unrestricted prescription of dabigatran: Is it safe in a resource-limited setting


Department of Critical Care Medicine, Fortis-Escorts Hospital, Neelam Bata Road, NIT, Faridabad, Haryana, India

Date of Web Publication24-Oct-2013

Correspondence Address:
Supradip Ghosh
Department of Critical Care Medicine, Fortis-Escorts Hospital, Neelam Bata Road, NIT, Faridabad, Haryana - 121 001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-5229.120335

Rights and Permissions




How to cite this article:
Ghosh S. Unrestricted prescription of dabigatran: Is it safe in a resource-limited setting. Indian J Crit Care Med 2013;17:325-6

How to cite this URL:
Ghosh S. Unrestricted prescription of dabigatran: Is it safe in a resource-limited setting. Indian J Crit Care Med [serial online] 2013 [cited 2017 Nov 22];17:325-6. Available from: http://www.ijccm.org/text.asp?2013/17/5/325/120335


Sir,

A 71-year-old grossly underweight male (about 52 kg), on dabigatran (110 mg twice daily) for paroxysmal atrial fibrillation, was admitted to our intensive care unit (ICU), with hemorrhagic shock following lower gastrointestinal bleeding. He was bedridden for past 3-months following right middle cerebral artery stroke and was on tracheostomy. He had recently undergone radical cystectomy with ileal conduit for bladder malignancy. His other comorbidities include hypertension and a history of stable coronary artery disease. He was also on aspirin, levetirecetam, and atorvastatin.

He was resuscitated with crystalloids, four units of packed red blood cells, and brief period of noradrenaline infusion. Six units of fresh frozen plasma were also transfused empirically (questionable benefit). Initial laboratory investigations showed hemoglobin: 5.7 g/dl, activated partial thromboplastin time: 49 s, international normalized ratio: 2.3, thrombin time >60 s (report received only after 4 days), and normal platelet count and hypoalbuminemia 2.1 g/dl. Hemodialysis was planned at the beginning but it took another 6 h in family counseling (and Nephrologist!), to arrange a dialysis machine, and finally start the dialysis (12-h after last dabigatran dose). In the following 24 h he continued to have deranged coagulation parameters and intermittent bleeding per rectum (albeit hemodynamically stable) requiring further transfusion. Colonoscopy showed diverticular disease with large ulcers and active ooze [Figure 1]. At 36-h in the ICU, he suffered cardiac arrest with monitor showing ventricular tachycardia. Repeat electrocardiogram done post-resuscitation showed new ST-segment elevation in anterior leads [Figure 2]. When explained, family refused further treatment and decided to take him home. On a telephonic follow-up 2 weeks after his discharge from the ICU, he was alive with apparently no change in his preadmission cognitive state.
Figure 1: Bleeding colonic diverticular ulcer

Click here to view
Figure 2: Electrocardiogram (ECG) showing ST elevation in the anterior leads

Click here to view


Reversal agent to dabigatran, that is, a neutralizing monoclonal antibody aDabi-Fab is limited to research setting. [1] Some of the measures suggested to stop dabigatran-induced bleeding [2] are either not available in many developing countries, for example, prothrombin complex concentrates including factor eight inhibitor bypassing activity or are not widely accessible, for example, hemodialysis or continuous venovenous hemofiltration.

Data regarding safety of dabigatran in elderly and underweight patients is sparse. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, largest study conducted on dabigatran, average weight of dabigatran treated patients in the 110 and 150 mg group was 82.9 and 82.5 kg, respectively; with only a sixth of patients having weight below 73 kg. [3] It is highly unlikely that RE-LY trial data can be extrapolated and used in an underweight patient like the present case. In a review of 78 bleeding episodes identified during an audit in Australia and New Zealand, advanced age was identified as one of the factors contributing to bleeding risk and this was compounded further by the presence of impaired renal function (common in elderly) and low body weight (<60 kg). [4] Bleeding risk in these frail elderly patient was not completely mitigated by dose reduction. [4]

In RE-LY trial, compared to warfarin, dabigatran was associated with a small but significant increase in the rate of myocardial infarction (MI). [3] In a recent meta-analysis of seven randomized control trials (n = 30,514), association of dabigatran with a higher risk of MI or acute coronary syndrome was confirmed further. [5] Till cardiac risk of dabigatran is further investigated, clinicians should apply caution in prescribing the drug to high-risk patients. [5]

Current case illustrates the limitations of prescribing dabigatran in resource-limited setting and a need for appropriate prescriber education program to restrict complications of therapy.


  Acknowledgment Top


I sincerely acknowledge the clinical contributions of staffs and doctors from Critical Care, Gastroenterology, Nephrology, Fortis-Escorts Hospital, Faridabad.

 
  References Top

1.Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for Dabigatran: Functional and structural characterization. Blood 2013;121:3554-62.  Back to cited text no. 1
    
2.Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013;41:e42-6.  Back to cited text no. 2
    
3.Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.  Back to cited text no. 3
    
4.Harper P, Young L, Merriman E. Bleeding risk with Dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.  Back to cited text no. 4
    
5.Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012;172:397-402.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2]

This article has been cited by
1 Potential use of NOACs in developing countries: pros and cons
Durga Bista,Leanne Chalmers,Luke Bereznicki,Gregory Peterson
European Journal of Clinical Pharmacology. 2014;
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Online since 7th April '04
Published by Wolters Kluwer - Medknow